PharmaNet hires vp for clinical operations

Catherine Derasp will oversee Phase I clinics

Catherine Derasp has joined PharmaNet Development Group, a US provider of clinical development services to the pharmaceutical and biotechnology industry, as vice president, clinical operations of the company's Phase I clinics.

Derasp will oversee the management of the company's 350-bed Phase I clinical operations that are located in Montreal and Quebec City, Canada. In addition to first-in-man and proof-of-concept phase I clinical services, she will be responsible for a variety of studies in special populations, cardiac safety testing, and drug-drug interaction studies.

You may also like

Regulatory
Early phase analytical strategy for biosimilars in a shifting regulatory landscape

Early phase analytical strategy for biosimilars in a shifting regulatory landscape

As FDA and EMA guidance continues to reinforce analytical comparability as the foundation of biosimilar development, investing in comprehensive early-stage characterisation is becoming essential to reduce uncertainty and improve development outcomes, says Dr Andrew J. Reason, CEO at BioPharmaSpec
Regulatory
AI in pharma: Practical use cases transforming research, regulatory and medical affairs

AI in pharma: Practical use cases transforming research, regulatory and medical affairs

AI and digital transformation expert Sarah Chan explores the rapidly expanding role of artificial intelligence across the pharmaceutical value chain
Manufacturing
DNA Script expands access to on-demand DNA synthesis in India through distributor agreement with Imperial Life Sciences

DNA Script expands access to on-demand DNA synthesis in India through distributor agreement with Imperial Life Sciences

Brings decentralised, in-house DNA synthesis capabilities to researchers in a rapidly growing biotechnology market
Pharmaceutical
Formulation freedom in clinical development: Why Fill2Weight matters

Formulation freedom in clinical development: Why Fill2Weight matters

As drug discovery accelerates, especially for poorly soluble small‑molecule compounds, formulation teams increasingly modify particle size, morphology and structure to improve dissolution in the body. This is precisely where 3P innovation’s proprietary Fill2Weight Gravimetric Powder Filler becomes a game‑changer
Regulatory
Nucleome Therapeutics secures US patent for Micro Capture-C 3D genomics technology

Nucleome Therapeutics secures US patent for Micro Capture-C 3D genomics technology

The USPTO grant strengthens Nucleome's global IP position around its Oxford-licensed MCC platform, which deciphers non-coding genetic variants to identify first-in-class drug targets — with lead inflammatory disease antibody NTP464 entering IND-enabling studies
Media
Plan your marketing strategy with Manufacturing Chemist

Plan your marketing strategy with Manufacturing Chemist

Discover upcoming special reports, themed features and commercial opportunities to help you connect with pharmaceutical manufacturing decision-makers throughout the year
Research & Development
Alzheimer’s Association launches $100m trial combining lifestyle changes and GLP-1s to prevent cognitive decline

Alzheimer’s Association launches $100m trial combining lifestyle changes and GLP-1s to prevent cognitive decline

The global study builds on US POINTER trial findings, testing whether adding a metabolism-targeting drug to structured lifestyle programmes can further reduce cognitive decline risk in at-risk older adults during a three-year period
Subscribe now